SCHEMBL456478

SCHEMBL456478

Clc1ccc(Cc2cccc3[nH]c(CN4CCCC4)nc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.49
GRIN2B Q13224 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
DRD4 P21917 4/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PARP1 P09874 2/20 0.43
MLLT1 Q03111 1/20 0.42
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
HIF1A Q16665 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
NR1I2 O75469 1/20 0.41
ABCB11 O95342 1/20 0.41
LMNA P02545 1/20 0.41
ESR1 P03372 1/20 0.41
PGR P06401 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8817554 0.83 PRNP (0.56) GRIN2BALDH1A1MAPTPRNPHTR6
SCHEMBL28072457 0.81 HTT (0.49) HTTCYP1A2CYP2D6DRD4KDM4E
SCHEMBL9015054 0.80 PRNP (0.46) GRIN2BLMNAMAPTPRNPOPRL1
SCHEMBL11116501 0.77 DRD4 (0.46) HTTGRIN2BCYP1A2CYP2D6DRD4
SCHEMBL162159 0.75 LTA4H (0.41) HTR2AMAPTPRNPHTR6
SCHEMBL11198298 0.74 MGAM (0.48) HTTDRD4ALDH1A1PARP1TDP1
SCHEMBL7483052 0.74 HTT (0.58) HTTGRIN2BCYP1A2CYP2D6DRD4
SCHEMBL7479734 0.73 HTT (0.61) HTTGRIN2BCYP1A2CYP2D6DRD4
SCHEMBL9015051 0.71 RAB9A (0.43) HTTGRIN2BKDM4ELMNAMAPT
SCHEMBL10690713 0.70 GAA (0.47) GRIN2BCYP1A2CYP2D6ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019070973-A1 CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS GLADIUS PHARMACEUTICALS CORPORATION (CA) 2019-04-11 WO disclosed
WO-2017079558-A1 TARGETING CASEIN KINASE-1 AND PI3K/AKT/mTOR PATHWAYS FOR TREATMENT OF C-MYC-OVEREXPRESSING CANCERS, ORGAN TRANSPLANT ASSOCIATED COMPLICATIONS AND AUTOIMMUNE DISEASES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-05-11 WO disclosed
WO-2016168911-A1 NUCLEOSIDE-BASED ANTI-BACTERIAL AND ANTI-PROTOZOAN DRUGS UTI LIMITED PARTNERSHIP (CA) 2016-10-27 WO disclosed
WO-2016160706-A1 INHIBITORS OF COLLAGEN PROLYL 4-HYDROXYLASE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2016-10-06 WO disclosed
EP-2668191-A2 BENZOFURO[3,2-C]PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA Albany Molecular Research, Inc. (US) 2013-12-04 EP disclosed
WO-2012099952-A2 BENZOFURO[3,2-C] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-26 WO disclosed
WO-2012034123-A1 ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C CORNELL UNIVERSITY (US) 2012-03-15 WO disclosed
EP-2328876-A1 ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Actimis Pharmaceuticals, Inc., (US) 2011-06-08 EP disclosed
WO-2010132810-A1 DEUTERIUM MODIFIED BENZIMIDAZOLES CONCERT PHARMACEUTICALS, INC. (US) 2010-11-18 WO disclosed
WO-2010118286-A2 BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN ACTIVITY AUSPEX PHARMACEUTICALS, INC. (US) 2010-10-14 WO disclosed
WO-2010027448-A1 ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ACTIMIS PHARMACEUTICALS INC. (US) 2010-03-11 WO disclosed
EP-1699760-A2 ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS Merck & Co., Inc. (US) 2006-09-13 EP disclosed
EP-1496898-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2006-05-10 EP disclosed
EP-1418900-A4 SELECTIVE ESTROGEN RECEPTOR MODULATORS MERCK & CO INC (US) 2006-01-25 EP disclosed
WO-2005062824-A2 ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS MERCK & CO., INC. (US) 2005-07-14 WO disclosed
EP-1496898-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2005-01-19 EP disclosed
EP-1418900-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2004-05-19 EP disclosed
WO-2003086314-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-10-23 WO disclosed
WO-2003015761-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-02-27 WO disclosed